- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03214614
A Study to Assess Safety, Tolerability and Pharmacokinetics of GLPG2451 in Healthy Male Subjects
Assessment of Safety, Tolerability and Pharmacokinetics of Multiple Ascending Oral Doses of GLPG2451 and of the Combination of GLPG2451 and GLPG2222 in Healthy Male Subjects
The study is a Phase I, randomized, double-blind, placebo-controlled study evaluating multiple ascending oral doses of GLPG2451 and the combination of GLPG2451 and GLPG2222 given for 14 days in healthy male subjects.
The purpose of the study is to evaluate the safety and tolerability of multiple ascending oral doses of GLPG2451 given to healthy male subjects compared to placebo, as well as of multiple oral doses of the combination of GLPG2451/GLPG2222 compared to placebo.
Study Overview
Status
Conditions
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
-
Antwerp, Belgium
- SGS LSS Clinical Pharmacology Unit Antwerp
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Male between 18 and 50 years of age inclusive, on the date of signing the Informed Consent Form (ICF).
- A body mass index (BMI) between 18-30 kg/m2, inclusive.
- Judged by the investigator to be in good health based upon the results of a medical history, physical examination, vital signs, 12-lead ECG, and clinical safety laboratory tests prior to the initial study drug administration. Clinical safety laboratory test results must be within the laboratory reference ranges or test results that are outside the reference ranges need to be considered non clinically significant in the opinion of the investigator. One retest is allowed during screening period, if deemed appropriate by the investigator.
Liver function tests must meet the following criteria: a. Aspartate aminotransferase (AST), ALT, or alkaline phosphatase (ALP) <1.5x ULN.
b. Bilirubin not greater than ULN, however documented Gilbert's syndrome is acceptable but no more than one subject with confirmed Gilbert's syndrome is allowed per cohort. One retest is allowed during screening period, if deemed appropriate by the investigator.
- Able and willing to comply with restrictions on prior and concomitant medication as described in the protocol.
- Non-smokers and non-users of any nicotine-containing products. A non-smoker is defined as an individual who has abstained from smoking for at least 1 year prior to screening. A non-user is defined as an individual who has abstained from any nicotine containing products for at least 1 year prior to the screening.
- Negative urine screen for drugs of abuse (amphetamines, barbiturates, benzodiazepines, cannabis, cocaine, opiates, methadone, and tricyclic antidepressants) and negative alcohol breath test.
- No evidence of lens opacity on slit lamp examination or similar system (e.g. ITrace technology).
- Agree to the use of a highly effective method of contraception (see protocol).
- Able and willing to sign the ICF as approved by the IEC, prior to any screening evaluations and willing to adhere to predefined prohibitions and restrictions.
Exclusion Criteria:
- Known hypersensitivity to study drug ingredients or a significant allergic reaction to any drug as determined by the investigator, such as anaphylaxis requiring hospitalization.
- Positive serology for hepatitis B virus surface antigen (HBs Ag), hepatitis C virus (HCV), or history of hepatitis from any cause with the exception of hepatitis A.
- History of or a current immunosuppressive condition (e.g., human immunodeficiency virus [HIV] infection).
- Clinically significant illness in the 3 months before the initial study drug administration.
- Presence or sequelae of gastrointestinal, liver, kidney (creatinine clearance ≤80 mL/min using the Cockcroft-Gault formula; if calculated result ≤80 mL/min, a 24-hour urine collection to determine actual value can be performed) or other conditions known to interfere with the absorption, distribution, metabolism, or excretion of drugs.
- History of malignancy within the past 5 years (except for basal cell carcinoma of the skin that has been treated and with no evidence of recurrence).
- Treatment with any drug known to have a well-defined potential for toxicity to a major organ in the last 3 months of 5 half-lives of the drug (whichever is the longer) before the initial study drug administration.
- Active drug or alcohol abuse (more than 3 glasses of wine or beer or equivalent/day) within 2 years prior to the initial study drug administration.
- Participation in a drug, drug-device combination or biologic investigational research study within 12 weeks or 5 half-lives of the investigational drug (whichever is the longer) prior to initial study drug administration.
- Any condition or circumstances that in the opinion of the investigator may make a subject unlikely or unable to complete the study or comply with study procedures and requirements.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: BASIC_SCIENCE
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: QUADRUPLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: GLPG2451 multiple dose
Multiple doses of GLPG2451 oral suspension at up to 3 dose levels in ascending order
|
GLPG2451 oral suspension, multiple ascending doses, daily for 14 days
|
PLACEBO_COMPARATOR: Placebo multiple dose
Multiple doses of Placebo oral suspension
|
Placebo, oral suspension, daily for 14 days
|
EXPERIMENTAL: GLPG2451/GLPG2222
Multiple doses of GLPG2451 oral suspension combined GLPG2222 oral suspension at up to 2 dose levels
|
GLPG2451 oral suspension and GLPG2222 oral suspension, multiple doses, daily for 14 days
|
PLACEBO_COMPARATOR: Combined Placebo multiple dose
Multiple doses of Combined Placebo oral suspension
|
Combined Placebo, oral suspension, daily for 14 days
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change versus placebo in the proportion of subjects with adverse events
Time Frame: Between screening and 154 days after the last dose
|
To assess safety and tolerability of multiple ascending doses and combination of GLPG2451 with GLPG2222 versus placebo in healthy subjects
|
Between screening and 154 days after the last dose
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Maximum observed plasma concentration of GLPG2451 (Cmax) given alone or in combination with GLPG2222
Time Frame: Between screening and 154 days after the last dose
|
To characterize the pharmacokinetics of GLPG2451 and its metabolite after multiple oral doses in healthy subjects
|
Between screening and 154 days after the last dose
|
Time of occurrence of Cmax for GLPG2451 given alone or in combination with GLPG2222
Time Frame: Between screening and 154 days after the last dose
|
To characterize the pharmacokinetics of GLPG2451and its metabolite after multiple oral doses in healthy subjects
|
Between screening and 154 days after the last dose
|
Area under the plasma concentration-time curve of GLPG2451 (AUC0-t) given alone or in combination with GLPG2222
Time Frame: Between screening and 154 days after the last dose
|
To characterize the pharmacokinetics of GLPG2451 and its metabolite after multiple oral doses in healthy subjects
|
Between screening and 154 days after the last dose
|
Ratio of 4-beta-hydroxycholesterol/cholesterol in plasma after multiple oral doses in healthy subjects
Time Frame: Day 1 predose and Day 14
|
To explore the potential of CYP3A4 interaction with GLPG2451
|
Day 1 predose and Day 14
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
- GLPG2451-CL-105
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Healthy
-
Prevent Age Resort "Pervaya Liniya"RecruitingHealthy Aging | Healthy Diet | Healthy LifestyleRussian Federation
-
Maastricht University Medical CenterCompletedHealthy Volunteers | Healthy Subjects | Healthy AdultsNetherlands
-
Yale UniversityNot yet recruitingHealth-related Benefits of Introducing Table Olives Into the Diet of Young Adults: Olives For HealthHealthy Diet | Healthy Lifestyle | Healthy Nutrition | CholesterolUnited States
-
Hasselt UniversityRecruitingHealthy | Healthy AgingBelgium
-
Galera Therapeutics, Inc.Syneos HealthCompleted
-
Galera Therapeutics, Inc.Syneos HealthCompletedHealthy | Healthy VolunteersAustralia
-
University of PennsylvaniaActive, not recruitingHealthy | Healthy AgingUnited States
-
Chalmers University of TechnologyGöteborg UniversityCompletedHealthy | Nutrition, HealthySweden
-
University of ManitobaNot yet recruitingHealthy | Healthy Diet
Clinical Trials on Placebo multiple dose
-
Galapagos NVCompleted
-
J2H BiotechCompletedNon-alcoholic SteatohepatitisKorea, Republic of
-
Astellas Pharma Europe B.V.CompletedPharmacokinetics of ASP1707 | Pharmacodynamics of ASP1707France
-
Guangzhou Henovcom Bioscience Co. Ltd.Completed
-
Janssen Research & Development, LLCCompleted
-
Bristol-Myers SquibbActive, not recruitingHealthy ParticipantsGermany
-
Sichuan Haisco Pharmaceutical Group Co., LtdCompleted
-
Kind Pharmaceuticals LLCCompleted